



Plenary Session 1

Sunday, October 18, 11:30 - 13:00

Session Title

THERANOSTICS: The Next Level

Chairpersons

Alexis Vrachimis (Limassol, Cyprus)

Shahneen Sandhu (Melbourne, Australia)

Programme

- 11:30 – 11:45 **Emma Aneheim** (Gothenburg, Sweden): Exciting New Isotopes for Therapy – Just a Trend?
- 11:45 – 12:00 **Thomas Hope** (San Francisco, United States of America): Rethinking FAP-Targeted Theranostics
- 12:00 – 12:15 **Xiaoli Lan** (Wuhan, China) – Integrin Directed Theranostics – Ready to Be a Success Story?
- 12:15 - 12:30 **Wolfgang Fendler** (Essen, Germany): RLT and Chemo – Combination or Competition?
- 12:30 – 12:45 **Shahneen Sandhu** (Melbourne, Australia): RLT + Immunotherapy: Unlocking Immune Synergies with Radioligands
- 12:45 - 13:00 **Constantinos Zamboglou** (Limassol, Cyprus): RLT + EBRT: Combining Systemic and Focal Radiation for Synergistic Tumour Control

Educational Objectives

1. Appreciate Challenges and Opportunities in Nuclear Medicine
2. Learn About the Scope of Emerging Therapeutic Radionuclides
3. Understand Limits But also Opportunities of Newly Translated Theranostics Concepts Targeting Integrins and Fibroblasts
4. Identify Combination Partners for Existing Theranostic Therapies

Summary

The field of theranostics is constantly changing. Innovation including new therapeutic radionuclides as well as new theranostic targets shape the future of our field. In this plenary session six outstanding speakers will carefully discuss new exciting therapeutic radionuclides, critically review emerging integrin- and fibroblast targeting theranostic advances, thoroughly summarize combination partners for established radioligand therapies such as PSMA RLT including chemotherapy, immunotherapy and EBRT among others. This is clearly a session nobody should miss.

Key Words

Trends and Challenges of Theranostics; Emerging Therapeutic Radionuclides; Integrin Targeted RLT; Fibroblast Targeted RLT; Combination Partners of PSMA RLT.